51. Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
- Author
-
Li-fen Han, Jian-ming Zheng, Li-qing Zheng, Hai-bing Gao, Li-xia Chen, Qing-ling Xu, Yi-hong Chai, Xin Zhang, Chen Pan, and Lv-feng Yao
- Subjects
Telbivudine ,Mother-to-child transmission ,Chronic hepatitis B ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background To evaluate the efficacy and safety of telbivudine in chronic hepatitis B women during the second and third trimesters of pregnancy. Methods The week 12–34 of pregnant women were screened in this prospective non-intervention study, with HBV DNA > 106 IU/mL and alanine aminotransferase > 50 IU/L. The patients were received telbivudine treatment as a treatment group or without antiviral treatment as a control group. All infants were received recombinant hepatitis B vaccine 10 μg within 12 h of birth, at week 4 and week 24, immunoglobulin G within 12 h of birth and were detected HBV markers at the range from 7 to 12 months after delivery. Results A total of 241 patients were finally enrolled, 139 patients in telbivudine group and 102 patients in control group. HBsAg negative rate of infants was 99.3% (135/136) in telbivudine group and was 91.9% (91/99) in control group after 7 months (P = 0.005), respectively. The incidence of undetectable HBV DNA levels (47.5%) was significantly lower in telbivudine-treated mothers than that in the controls (0%), and 75.5% patients alanine aminotransferase returned to normal in telbivudine group, and 51% in control group at delivery (P
- Published
- 2019
- Full Text
- View/download PDF